TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a proven and documented diagnosis of non Cystic Fibrosis (CF) idiopathic or post infectious bronchiectasis~* Stable pulmonary status and stable regimen of standard treatment at least for the past 4 weeks~Exclusion Criteria:~* Forced expiratory volume in 1 second (FEV1) \<30% or \>90% predicted~* Active allergic bronchopulmonary aspergillosis~* Active and actively treated non tuberculosis mycobacterial (NTM) infection or tuberculosis~* Primary diagnosis of Chronic obstructive pulmonary disease (COPD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciprofloxacin DPI 28 Days on/off (Cipro 28) (Type: EXPERIMENTAL): Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
- Ciprofloxacin DPI 14 Days on/off (Cipro 14) (Type: EXPERIMENTAL): Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
- Placebo 28 Days on/off (Placebo 28) (Type: PLACEBO_COMPARATOR): Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
- Placebo 14 Days on/off (Placebo 14) (Type: PLACEBO_COMPARATOR): Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfill the diagnostic criteria for major depression according to the Diagnostic and Statistical Manual of Mental Disorders (most recent edition)~* Failure to respond to at least 2 adequate drug therapies for the current depression episode~* MADRS score of 20 or above (moderate - severe~* ASA physical status classification I to III~Exclusion Criteria:~* Inability to obtain informed consent~* ASA physical status classification IV~* Complication by any serious physical diseases such as cardiovascular disease (including untreated HTN), respiratory disease, cerebrovascular disease, intracranial HTN (including glaucoma), or seizures~* Presence of foreign body (including pacemaker)~* Pregnancy~* Allergies to anesthetics used in study Includes: a) Ketamine b) Propofol c) Eggs d) Egg products e) Soybeans f) Soy products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
- Ketamine (Type: EXPERIMENTAL): Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ESPB vs FICB for Pain Management Following Total Hip Prosthesis Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ASA classification I-III~* Aged 18-80 years~* Who will be scheduled for total hip prosthesis surgery under spinal anesthesia~Exclusion Criteria:~* Patients who have a history of bleeding diathesis~* Take anticoagulant therapy~* History of chronic pain before surgery~* Known local anesthetics and opioid allergy~* Pregnancy or lactation~* Infection at the site of block~* Patients who do not accept the procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GroupFICB= fascia iliaca compartment block (Type: ACTIVE_COMPARATOR): ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and then for correction of the needle 2 ml saline will be injected deep into the erector spinae muscle fascia. Following confirmation of the correct position of the needle 30 ml 0.25% bupivacaine will be administered for the block.
- Group ESPB = erector spina plan block (Type: ACTIVE_COMPARATOR): FIC block will be performed in the supine position. The linear probe is placed transversely to identify the femoral artery, iliopsoas muscle, and fascia iliaca at the inguinal crease. The probe will be tilted cranially and caudally until optimal images of the fascia iliaca are obtained. Block needle (50 mm, 22G) will be passed through the iliac fascia via the in-plane method. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sign Informed Consent.~* 21 years of age or older.~* Able to follow instructions and willing to attend required study visits.~* Clinical diagnosis of ocular hypertension, primary open-angle, or pigment dispersion glaucoma in at least one eye (qualifying eye).~* Intra-ocular pressure (IOP) considered to be safe in both eyes in such a way that should assure clinical stability of vision and the optic nerve throughout the trial.~* Must have best corrected visual acuity of 6/60 (6/60 Snellen, 1.0 LogMAR) or better in each eye.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Presence of other primary or secondary glaucomas not listed in inclusion criterion.~* Presence of corneal dystrophies.~* Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.~* Intraocular conventional surgery or laser surgery in qualifying eye(s) less than three months prior to Visit 1.~* Risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's best judgment.~* Women of childbearing potential not using reliable means of birth control.~* Women who are pregnant or lactating.~* Participation in any other investigational study within 30 days prior to Visit 1.~* Current or anticipated use of systemic corticosteroids, by any route except inhaled, for greater than two weeks during the trial.~* Severe allergic rhinitis~* History of ocular herpes simplex.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brinzolamide/Timolol Maleate Fixed Combination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient has a diagnosis of IBS by Rome III criteria with a subtype of diarrhea~* Female patients must be:~* postmenopausal, defined as amenorrhea for at least 2 years at Prescreening,~* surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),~* abstinent, or~* if sexually active, be practicing an effective method of birth control.~Key Exclusion Criteria:~* Patient has a diagnosis of IBS by Rome III criteria with a subtype of constipation, mixed IBS, or unsubtyped IBS~* Patient has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease~* Patient has a history of diverticulitis within 6 months prior to Prescreening~* Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, impaired intestinal circulation (eg, aortoiliac disease), thrombophlebitis of a major vein, or hypercoagulable states.~Other protocol-specific eligibility criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eluxadoline 5 mg (Type: EXPERIMENTAL): Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks.
- Eluxadoline 25 mg (Type: EXPERIMENTAL): Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
- Eluxadoline 100 mg (Type: EXPERIMENTAL): Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks.
- Eluxadoline 200 mg (Type: EXPERIMENTAL): Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Treatment for Hypogonadal Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Low T males 18 - 80 years of age~Exclusion Criteria:~* Normal T levels~* Elevated Prostatic Specific Antigen (PSA)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- T-Gel 1.62% (Type: EXPERIMENTAL): Testosterone (T) gel 1.62%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C \> 70 mg/dL and Triglycerides \< 400 mg/dL,~* Treated with a high-intensity statin therapy~Exclusion Criteria:~* BMI \>= 40 kg/m2~* Significant cardiovascular disease~* HbA1c \>= 10%~* Uncontrolled hypertension~* Active muscle disease~* estimated glomerular filtration rate \< 60 mL/min~* Hepatic dysfunction~* History of participation in any clinical trial evaluating obicetrapib~* Anemia~* History of malignancy~* Alcohol abuse~* Treatment with investigational product~* Treatment with PCSK9~* Clinically significant condition~* Known CETP inhibitor allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): once-daily placebo tablet and placebo capsule
- monotherapy (Type: EXPERIMENTAL): once-daily obicetrapib 10 mg tablet and placebo capsule
- combination therapy (Type: EXPERIMENTAL): once-daily obicetrapib 10 mg tablet and ezetimibe 10 mg capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with ulcerative colitis diagnosed prior to screening~* Participants should have current treatment for ulcerative colitis with at least one of the following therapies: oral 5-aminosalicylates (5-ASAs), oral corticosteroids, 6-mercaptopurine (6-MP), or azathioprine (AZA)~* Participants must have a history of failure to respond to, or tolerate, at least 1 of the following therapies: oral 5-ASAs, oral corticosteroids, 6-MP, or AZA~* Participants must be ambulatory and have moderately to severely active ulcerative colitis confirmed during the screening sigmoidoscopy by a greater than or equal to 2 using the endoscopy subscore of the Mayo score~* Participants must have moderately to severely active ulcerative colitis, defined as a baseline Mayo score of 6 to 12, inclusive~Exclusion Criteria:~* Participants with ulcerative colitis limited to the rectum only or to less than 20 cm of the colon~* Participants with stoma~* Participants with fistula or history of fistula~* Participants who require, or required within the 2 months prior to screening, surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage, or other conditions possibly confounding the evaluation of benefit from study agent treatment~* Participants with symptomatic colonic or small bowel obstruction, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Golimumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of perennial allergic rhinitis (PAR).~* Must comply with study procedures and be literate.~Exclusion criteria:~* Significant concomitant medical conditions.~* Use of corticosteroids.~* Use of allergy medications and some other medications during the study.~* Current tobacco use.~* Clinically significant abnormal ECG or laboratory abnormality.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effects of US Bilateral Rectus Sheath Block for Laparoscopic GY Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multi-port laparoscopic gynecologic surgery~* American society of Anesthesiologists (ASA) physical status classification I-II~* Age: 21-60~Exclusion Criteria:~* Gynecologic cancer operation~* History of previous abdominal surgery~* Allergy to local anesthetics(ropivacaine)~* Opioid tolerance~* Coagulopathy~* Infection at the needle insertion site~* Difficulty to cooperating

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rectus sheath block (Type: EXPERIMENTAL): Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
- Control (Type: SHAM_COMPARATOR): Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer treated in the past 3 years~Exclusion Criteria:~* Dementia~* Psychotic Disorder~* In hospice care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1. Yoga therapy (Type: ACTIVE_COMPARATOR): The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
- 2. Wait list (Type: NO_INTERVENTION): The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Speak and read English~* Have had vaginal intercourse in the past three months~Exclusion Criteria:~* Are pregnant~* Are trying to conceive

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- CDC Poster (Type: ACTIVE_COMPARATOR): After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
- Patient-Centered Poster (Type: EXPERIMENTAL): After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years and older at index date~* Diagnosis of MM~* Measurable disease according to IMWG criteria~* ECOG performance status ≤2~* Refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 treatment (ie, triple-class refractory \[TCR\])~* At least 1 treatment following their TCR eligibility~Exclusion Criteria:~* Acute plasma cell leukemia~* Amyloidosis~* Smoldering MM~* Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)~* Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ~* Administration with an investigational drug within 30 days prior to index

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elranatamab (Type: None): Patients treated with elranatamab from the MagnetisMM-3 trial
- Standard of care (Type: None): Patients treated with standard-of-care therapies from real-world data sources

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete